

# Planning for success: overcoming challenges to recruitment and conduct of an open-label emergency department-led paediatric trial

Louise Roper, <sup>1</sup> Mark D Lyttle, <sup>2,3</sup> Carrol Gamble, <sup>4</sup> Amy Humphreys, <sup>4</sup> Shrouk Messahel, <sup>5</sup> Elizabeth D Lee, <sup>5</sup> Joanne Noblet, <sup>5</sup> Helen Hickey, <sup>4</sup> Naomi Rainford, <sup>4</sup> Anand Iyer, <sup>6</sup> Richard Appleton, <sup>6</sup> Kerry Woolfall <sup>1</sup>

#### Handling editor Edward Carlton

► Additional material is published online only. To view please visit the journal online (http://dx.doi.org/10.1136/ emermed-2020-209487).

<sup>1</sup>Institute of Population Health & Society, University of Liverpool, Liverpool, UK

<sup>2</sup>Emergency Department, Bristol Royal Children's Hospital, Bristol,

<sup>3</sup>Faculty of Health and Applied Sciences, University of the West of England, Bristol, UK

<sup>4</sup>Liverpool Clinical Trials Centre, University of Liverpool, Liverpool,

<sup>5</sup>Emergency Department, Alder Hey Children's NHS Foundation Trust Liverpool UK <sup>6</sup>Department of Neurology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK

#### Correspondence to

Dr Kerry Woolfall, University of Liverpool Liverpool L69 3BX. UK; k.woolfall@liverpool.ac.uk

Received 29 January 2020 Revised 3 August 2020 Accepted 1 September 2020 Published Online First 13 October 2020

#### **ABSTRACT**

**Background** Key challenges to the successful conduct of The Emergency treatment with Levetiracetam or Phenytoin in Status Epilepticus in children (EcLiPSE) trial were identified at the pre-trial stage. These included practitioner anxieties about conducting research without prior consent (RWPC), inexperience in conducting an ED-led trial and use of a medication that was not usual ED practice. As part of an embedded study, we explored parent and practitioner experiences of recruitment, RWPC and conduct of the trial to inform the design and conduct of future ED-led trials.

**Methods** A mixed-methods study within a trial involving (1) guestionnaires and interviews with parents of randomised children. (2) interviews and focus groups with EcLiPSE practitioners and (3) audio-recorded trial discussions. We analysed data using thematic analysis and descriptive statistics as appropriate.

Results A total of 143 parents (93 mothers, 39 fathers, 11 missing information) of randomised children completed a questionnaire and 30 (25 mothers, 5 fathers) were interviewed. We analysed 76 recorded trial recruitment discussions. Ten practitioners (4 medical, 6 nursing) were interviewed, 36 (16 medical, 20 nursing) participated in one of six focus groups. Challenges to the success of the trial were addressed by having a clinically relevant research question, pragmatic trial design, parent and practitioner support for EcLiPSE recruitment and research without prior consent processes, and practitioner motivation and strong leadership. Lack of leadership negatively affected practitioner engagement and recruitment. EcLiPSE completed on time, achieving its required sample size target.

**Conclusions** Successful trial recruitment and conduct in a challenging ED-led trial was driven by trial design, recruitment experience, teamwork and leadership. Our study provides valuable insight from parents and practitioners to inform the design and conduct of future trials in this setting.

### Key messages

### What is already known on this subject

- ► The 'Emergency treatment with Levetiracetam or Phenytoin in Status Epilepticus in children (EcLiPSE)' trial was one of the first UK paediatric clinical trials of an interventional medicinal product to be conducted since legislation change enabling research without prior consent (RWPC).
- Pre-trial research identified challenges to the success of EcLiPSE including use of an antiepileptic medication (levetiracetam), which was not the standard medication in this clinical setting; practitioner anxieties about RWPC and inexperience of conducting an ED-led trial; healthcare staff rotational posts; and availability to seek consent.

### What this study adds

- ► In this mixed-methods embedded study to explore parent and practitioner involvement in EcliPSE.
- ► Challenges to trial success were overcome through trial design, recruitment experience, parental support for RWPC, and teamwork and leadership.
- ► Our study provides valuable insight from parents and practitioners to inform the design and conduct of future trials in this setting, including consideration of how the study and RWPC could be briefly communicated to parents of children who are regular ED attenders at the point of randomisation if deemed appropriate.
- Further research is needed to evaluate whether findings and recommendations translate to other ED-led trials of treatments for critically ill children.



@ Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

To cite: Roper L, Lyttle MD, Gamble C, et al. Emerg Med J 2021;38:191-197.

### INTRODUCTION

Recruitment to multicentre randomised controlled trials is challenging, and poor recruitment can lead to reduced confidence in the results, costly extensions or early closure. Trial recruitment can be hindered by patient and trial practitioner-related factors including poor quality participant information, practitioner workload pressures, lack of equipoise, lack of leadership, or poor collaboration between clinical specialities and research teams.<sup>23</sup> Trials conducted in paediatric emergency medicine encounter additional practical and ethical challenges, including the need to perform research in life-threatening situations. To help ensure this research can be conducted, clinical trials legislation enables children to be enrolled into some





consent (RWPC) is largely acceptable to parents and children, yet they may have concerns if trial interventions are not part of routine clinical care.<sup>67</sup> Studies have also shown how practitioners without experience of RWPC may have negative perceptions of this consent method, <sup>8 9</sup> particularly if trial interventions

The 'Emergency treatment with Levetiracetam or Phenytoin in Status Epilepticus in children (EcLiPSE)' was an open-label, clinician-led trial and one of the first UK critical care trials of an interventional medicinal product to be conducted since legislation change enabling RWPC. Challenges to the success of EcLiPSE trial were identified in pre-trial research<sup>10</sup> and site training. 11 These included use of an anti-epileptic medication (levetiracetam), which was not the standard medication; inexperience of conducting an ED-led trial in a paediatric neurological emergency; practitioner anxieties about RWPC, including how parents would react to trial processes taking place without their consent, such as the opening of a randomisation envelope; healthcare staff rotational posts; and availability to seek consent. Despite these challenges, the EcLiPSE trial successfully recruited to target on time.

Consent Study) involving parents of randomised children and EcLiPSE practitioners to explore experiences of recruitment, RWPC and trial conduct to inform the design and conduct of future ED-led trials. In this manuscript, we explore Consent Study data to identify key obstacles and enablers for successful trial conduct. A framework to enhance practitioner explanations and parental understandings of research without prior consent is reported in a separate manuscript (in press).

#### **METHODS**

A mixed-methods embedded study (the Consent Study) took place in all 30 EcLiPSE sites between July 2015 and April 2017. This involved questionnaires and interviews with parents of randomised children, interviews and focus groups with EcLiPSE practitioners, and audio-recorded trial discussions. KW (female social scientist, PhD) and LR (female health psychologist, PhD) developed questionnaires (online supplemental file 1), and interview and focus group topic guides, using previous relevant studies<sup>5</sup> and EcLiPSE feasibility work, which outlined parents' views on trial acceptability and feasibility, including potential burden of the intervention and approach to consent<sup>10</sup> (see example questions in online supplemental file 2). Topic guides and questionnaires explored experiences of trial recruitment and consent process, trial acceptability, and perceived barriers and facilitators to trial conduct. Recorded trial discussions between parents and recruiting practitioners enabled additional insight into trial recruitment and RWPC conversations.

Parents/legal representatives who did and did not consent to their child's participation in the trial, and all practitioners involved in screening, recruiting, randomising and consenting were eligible to take part. Verbal consent was sought for audio recording trial conversations between parents and recruiting practitioners before study discussions began. If verbal consent was provided, a digital recorder was used to record trial discussions. Written consent was then sought for all Consent Study elements as part of the EcLiPSE consent process. Recruitment for the Consent Study began at the same time sites began recruitment to EcLiPSE. This included written parental consent for the use of recorded trial discussion data, completion of Consent

ings of research without prior consent are reported in a separate manuscript (in press). We present selected interview quotations (with pseudonyms) that illustrate research themes across a range of participants within the results. Where quotes have been shortened for brevity or to remove identifiable information, omitted text is marked with '...' and explanatory text is in brackets. Participants were given consecutive identifying numbers, but cross-checked when presenting quotations for this manuscript to ensure no participant was cited twice with different identifying numbers. Descriptive statistics are presented with percentages.

### Patient and public involvement

Details of patient and public involvement activities are reported in our linked publication (in press).

### RESULTS

A total of 218 parents of 289 (75%) randomised and treated children consented to participate in some aspect of the Consent Study, and 143 parents completed a questionnaire (figure 1). We reached data saturation<sup>14</sup> at 76 recorded trial discussions, 30 parent (25 mothers, 5 fathers) interviews, 6 practitioner focus groups (n=36) and 10 practitioner telephone interviews. All parents interviewed had completed a questionnaire. Practitioners (nurses, n=26; doctors, n=20) included Principal Investigators,

data mining, AI training, and similar technologies.

Protected by copyright, including for uses related to text

Table 1   Approach to data analysis and synthesis		
Phase	Description	
1. Familiarising with qualitative data	LR read interview, focus group, audio recorded consent discussion transcripts noting down initial ideas on themes	
2. Generating initial codes	Initially, three complementary data-coding frameworks were developed (for focus group, interview and audio-recorded consent discussion data) using broad a priori codes identified from initial reading related to the Consent Study aims and objectives. During the familiarisation stage, LR and KW identified data-driven codes and concepts. Analysis was based on thematic analysis, a method for identifying, analysing and reporting patterns (or themes) within data	
3. Developing the coding framework	LR coded three transcripts in each data set and shared the initial coding frameworks with KW. KW second coded transcripts using the initial coding frames and made notes on any new themes identified and how the framework could be refined	
4. Defining and naming themes	Following review and reconciliation by LR, revised coding frames were subsequently developed and ordered into themes (nodes) within the NVivo Database. Regular meetings were held to discuss the developing frameworks	
5. Completion of coding of transcripts	LR completed coding transcripts. For this manuscript, KW reviewed coding specific to challenges and enablers of conducting the trial and conducted further coding across datasets and made notes on in preparation for writing this manuscript	
6. Quantitative data analysis	LR entered questionnaire data into SPSS. Descriptive statistics were conducted including $\chi^2$ test for trend	
7. Data synthesis	Our approach to synthesising qualitative and quantitative data <sup>25</sup> drew on the constant comparative method. <sup>12</sup> <sup>13</sup> This involved KW looking across quantitative and qualitative datasets for themes/data output related to challenges and enablers to successfully conducting research in paediatric emergency situations. This included exploring qualitative themes and quantitative output related to parent and practitioner experiences of recruitment, RWPC and conduct of the trial. Analysis was interpretive—theorising the significance of the patterns and their broader meanings and implications	
8. Write-up	LR and KW developed the initial manuscript. KW led the final development of themes and write-up phase in collaboration with LR and MDL.	
RWPC, research without prior consent.		

Emergency Medicine doctors, and clinical and research nurses. Focus groups were held a mean 12 months and 9 days (range 329-420) after site opening. Telephone interviews took place 5–16 months (mean 8 months and 21 days, range 168–490 days) after site opening. No practitioners in our sample had prior experience of RWPC in paediatric trials.

### Importance of a clinically relevant research question and pragmatic trial design

Practitioners described how the EcLiPSE Study addressed "a really important question that people want answered" (Focus group 3, female, doctor P4). This importance appeared to facilitate buy-in and enthusiasm for trial recruitment. Parents also spoke of how the trial aimed to answer a clinical question which they felt was important, with many explaining how they valued research that explores treatments for their child's condition.

"I think the importance is I guess the clinical question. I think [this] is when you get maximum engagement from the clinical team" (Practitioner telephone interview, male, lead research nurse, P9).

"As the mother of a child that goes into Status and gets severe seizures it's nice to know that people are looking at studies" (Recorded trial discussion 41, parent).

Parents whose children had regular seizures described how they saw potential for their child to benefit from trial findings in the future "if it happened again" (Parent interview, mother, P28). Our pre-trial feasibility work<sup>10</sup> had identified inexperience of conducting research during resuscitation as a potential challenge to recruitment. However, during focus groups and interviews, many practitioners described how EcLiPSE trial processes had been easy to follow in an emergency situation. A pragmatic design, which fitted closely to usual clinical practice and did not involve "extra work" (Focus Group 2, female, nurse, P4), was valued and appeared to assist practitioner engagement.

#### AWARENESS OF RANDOMISATION IN THE ED

An evaluation of EcLiPSE site training<sup>11</sup> indicated practitioners were concerned that if parents noticed randomisation envelopes being opened in the ED, they would object to the trial, or

RWPC. They feared this would cause friction in a highly emotive life-threatening situation.

"You're like oh my God, what are they [parent] going to say, what are they going to do" (Practitioner telephone interview, female, lead research nurse, P8).

However, when reflecting on their experience of randomisation, practitioners described how such initial concerns were often not realised as "parents are focussed on their child" (Focus group 2, male doctor, P1) and if they had noticed the envelope, it was often a passing recognition. Such findings were supported by the majority of parents who recalled how they "didn't really have the time or inclination to think about it" (Parent interview, mother, P19).

The few parents in our sample who had noticed randomisation taking place in the ED were mainly those with previous experience of their child being admitted to hospital with seizures.

"When you've got a parent who has a child that's a known epileptic and so they know all of the normal words that are said around that and then suddenly it's a different one and they're like what does that mean?" (Focus group 5, nurse, P6)

In the cases when a parent did notice a change, a brief discussion about the study, including what drug had been allocated, made parents feel that practitioners "were keeping me involved" (Parent interview, mother, P15). This communication appeared to alleviate any potential concerns or negative responses.

"It was after, obviously, the doctor had told me but I had seen them open the envelope, which is obviously new... I think as they opened the letter they would tell me what drug they were using, they always do" (Parent interview, mother, P7).

Practitioners described how the provision of brief information about EcLiPSE and being "really transparent" (Focus group 2, female, nurse, P6) when experienced parents noticed something different was important in maintaining parental trust. However, it was not always possible for practitioners to know whether parents had noticed trial processes were taking place. One parent had noticed the randomisation process, but had not

training, and similar technologies

## 289 children randomised and treated in EcLiPSE 218 (75%) parents of randomised children consented to participate in at least one aspect of the consent study Recorded trial discussion (n=76) Approached for recording and consented: n= 95/193, 49% Declined: n= 98/193, 51% Recordings received and analysed: n = 76/95, 80% Parent questionnaire (n=143) Approached for questionnaire and consented: n= 212/289, 73% Declined: n= 45/289, 15%, Not approached: n=11/289, 3% Not received n=66/212, 31% Questionnaires received: n= 143/212.67% Mothers: n = 93/143.65%Father: n= 39/143, 27% Parents telephone interview (n=30) Approached for interview and consented: n= 114/193, 59% Declined: n= 79/193, 31% Contacted for telephone interviews: n= 59/114 (51%) No response to contact: n=10/59, 16% Incorrect details: n= 8/59, 13% Declined when contacted: n= 11/59, 18% Mothers: n= 25, 83% Fathers: n=5, 16% 6 Staff Focus Groups (n=36) Nurses approached and consented: n= 20, 56% Doctors approached and consented: n= 16, 44% Declined: n= 0, 0% Staff interviews (n=10) Nurses: approached and consented n=6, 60% Doctors approached and consented: n=4, 40%

Declined: n= 0, 0% Figure 1 Participant characteristics by method in chronological order.

asked questions on noticing the clinical team were whispering about something; this led to parental suspicion:

"I'm like what's all this whispering about? What's the dodgy envelope? My kid is unconscious, tell me what's going on. So it definitely made me uncomfortable" (Recorded trial discussion 52, parent).

### Parent and practitioner support for EcLiPSE recruitment and consent processes

Just over one-third of parents (56/143, 39%) who completed a questionnaire indicated they were surprised to find out their child had been enrolled into a trial. However, almost all (139/143; 97%) agreed with the questionnaire statement that they "understood why consent for my child's participation in EcLiPSE was sought after the treatment was given", while the majority (129/143, 90%) also indicated they were satisfied with the EcLiPSE consent process. In contrast, one mother described her sense of loss of control over the situation as "They'd done it

without telling us" (Parent interview, mother, P11). However, she explained how she provided consent for the use of her child's data in EcLiPSE as "They use these two medications all the time", which she found reassuring. As the following quote illustrates, the majority of parents stated that in such a life-threatening situation, parents prioritised the emergency treatment of their child over research consent processes:

"Well I prefer them to do whatever they can. It doesn't really matter too much about consent, as long as they can do what they can to stop a seizure or to help stabilise, that is the first and foremost" (Parent interview, mother P3).

Support for RWPC was also described during practitioner interviews and focus groups, which was mainly attributed to "really positive responses" (Practitioner telephone interview, female, doctor, P9) from parents to RWPC discussions.

### Adapting to research: going above and beyond

Protected by copyright, including for uses related to text Evaluation of site initiation training<sup>11</sup> highlighted concerns surrounding research personnel being available to support clinical teams, leading to patients being missed, or inability to seek consent during evenings, weekends and the busy winter period. Despite best efforts, a minority of sites described how they struggled to work as a team due to lack of research support or engagement by key practitioners.

"I think not having [nurse] working in research, well that hasn't helped. I mean just having him there two days that has kind protected time... But even when he was working with us, I don't think we were necessarily always completing a log screen for every single case" (Practitioner telephone interview, male, lead research nurse, P9).

However, most sites overcame these challenges and successfully recruited to target, with some sites involved in multiple clinical trials having sufficient research cover at weekends. More commonly, practitioners described how they had "come in on your time off" (Practitioner telephone interview, female, doctor, P6). Some high recruiting sites developed methods to maintain trial awareness and ensure eligible patients were not missed, including placing study materials in common areas or resuscitation rooms (eg, posters and leaflets), small non-financial staff incentives, and raising awareness of their recruitment performance in comparison with their own target, and other sites.

### Facilitating trial conduct through leadership

Despite some initial concerns about capacity, site leads acted as advocates for the study, maintaining awareness and regular training:

"We had taken on the study so we were very keen to do it. Even though we internally had our concerns, we were very strong at promoting it after we had that initial site visit" (Practitioner telephone interview, female, doctor, P3).

Practitioners emphasised the importance of Principal Investigators taking responsibility for promoting the trial and recruitment of patients 24/7. This was often challenging in EDs working at full capacity. Examples included Principal Investigators preparing resuscitation teams when a potentially eligible child was on their way to the ED in order to briefly refresh people's minds about the trial and clarify details of the scenario that may unfold.

"Just, if after the alert, you'd said to whichever nurses are in resus, okay, we've got a fitter, we might be doing the EcLiPSE study, are you all aware of that? ... What's going to happen is..." (Focus group 6, male, doctor, P1).

Strong leadership was not evident at a few sites, which generated negative impact on practitioner engagement, and lower numbers enrolled. Although such examples were rare, they highlight the importance of identifying a motivated Principal Investigator who is willing to make time to support the study throughout trial conduct.

"Sorry to be a bit miserable about it, but we do struggle a little bit with maintaining any enthusiasm... nobody is taking ownership really" (Practitioner telephone interview, female, lead research nurse, P1).

#### **DISCUSSION**

This study provides insight into the key factors which enabled successful conduct of a challenging ED-led paediatric emergency care trial drawing on the perspectives of parents of participants, and trial practitioners. Multiple factors, including trial design, tailored communication with parents of regular attenders, research support, teamwork and leadership, contributed strongly to successful conduct at each site and across the trial as a whole. There was a perceived negative impact on team engagement and recruitment where such factors were lacking.

Importantly, both parents and practitioners wanted to know the answer to the research question, a factor that appeared to underpin many of the decisions and behaviours captured in our embedded study. For example, the perceived importance of the clinical question appeared to influence parents' consent decision as many believed their child may benefit from trial findings in the future. This was not a misconception for parents of eligible children with a chronic health condition, as it was feasible that the trial results could inform changes to clinical care decisions within their lifetime. Our findings also suggested that practitioners were engaged and invested in EcLiPSE due to its design. The trial was open label, pragmatic and clinician led, and aimed to answer an important question that they believed would quickly inform their clinical practice. This engagement was apparent across the majority of EcLiPSE sites, despite initial concerns about whether the trial was possible which were often confounded by inexperience of conducting an ED-led trial. Our findings highlight the important role of researchers and funding panels in identifying clinically important research questions and suggest that challenging trials are more likely to succeed if all key stakeholders, including patients, family members and clinicians, prioritise the research question.<sup>15</sup>

Literature on pragmatic clinical trials has emphasised the importance of understanding the trial context. <sup>16</sup> ED practitioners valued how the EcLiPSE trial protocol was easy to follow, as it fitted closely to the usual emergency care algorithm for Status Epilepticus. Our findings suggest that work undertaken by the EcLiPSE team, which included ED nurses, doctors, neurologists and triallists, who streamlined intervention delivery and data collection processes to minimise burden, contributed to successful recruitment and conduct in this setting.

As shown in recent pilot studies exploring treatments for paediatric suspected infection, <sup>17</sup> <sup>18</sup> parents and practitioners found RWPC to be acceptable, preventing unethical delays in the delivery of life-saving treatments. Our study adds to this literature by providing further insight into RWPC processes through a mixed-methods approach, including audio-recorded recruitment discussions and interviews with both parents and recruiting practitioners. We found that initial practitioner concerns that parents

Box 1 Communication of RWPC to parents of regular attenders in the ED

If deemed appropriate, consider explaining how:

- We are conducting a study looking at [add key aim].
- Currently treating your child is the priority. We will of course talk to you about the study as soon as possible after the emergency situation has passed.
- If you would like further information about the study now, we have an information leaflet [direct parent to leaflet and/ or posters].

If parents state that they do not want their child included while in the ED, then they should not be included.

would notice the randomisation envelope and object to the trial, or RWPC, were most often unfounded. Parents of children with frequent seizures appeared more likely to notice something different was occurring in the ED, such as the opening of the randomisation envelope. These parents valued how practitioners provided them with brief description of the study, including what drug had been allocated. One instance where such communication had not occurred had resulted in parental suspicion and potential breakdown of a trust in practitioners. Practitioners confirmed that brief information sheets and EcLiPSE posters were on display, although few parents noticed or read them. As shown in other studies exploring trial recruitment and decisionmaking, <sup>19 20</sup> patients and family members often prioritise verbal over written information provision. The highly stressful and 5 time-critical ED context is likely to have impacted on parental capacity and indeed desire to read even short written study information.<sup>5</sup> Future trials would benefit from considering how their study and RWPC could be briefly communicated to parents of children who are regular ED attenders at the point of randomisation if deemed appropriate. Box 1 contains suggested brief information used in EcLiPSE practitioner training, which has been adapted for future ED trials.

Lemiex-Charles and McGuire's Integrated Team Effectiveness Model (ITEM)<sup>21</sup> provides a conceptual framework to aid the assessment of teams in healthcare. ITEM outlines the interplay between task (eg, trial) design and processes in achieving team effectiveness, while highlighting the importance of organisational context in which teams are embedded. At some sites, EcLiPSE recruitment was challenged by lack of ringfenced research staff time, or a lack of engagement of key site leads, which led to lower recruitment at these sites. Nevertheless, the majority of recruitment was challenged by lack of ringfenced research staff sites did not experience or overcome such challenges. Many went above and beyond their expected roles, by working in their own time, <sup>22</sup> developing internal team rota systems and team incentives to facilitate recruitment. Although we believe this was intrinsically linked to practitioner engagement and support for a pragmatic trial, qualitative data suggest that leadership from a pragmatic trial, qualitative data suggest that leadership from the trial team and site Principal Investigators were also contributing factors. Indeed, a lack of leadership at a few sites negatively impacted on practitioner engagement. Practitioners valued regular communication and support from the EcLiPSE team, which included members of the Pediatric Emergency Research in the UK and Ireland (PERUKI) research collaborative. <sup>23</sup> As shown in other studies, <sup>24</sup> regular multidisciplinary meetings, including teleconference or annual face-to-face PERUKI meetings, were viewed as a useful method of sharing good practice and maintaining enthusiasm.

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

### Original research

### Limitations and future directions

Our embedded study is potentially limited as it relates to only one ED-led trial of treatments for Status Epilepticus in the UK. Further research is needed to evaluate whether findings and recommendations translate to other ED-led trials of treatments for critically ill children. Our study was strengthened by a mixed-methods approach to gain insight into both parent and practitioner experiences of trial recruitment and conduct. All sites participated in the Consent Study and practitioners were purposively sampled for focus groups and interviews to ensure sample variance (eg, low and high recruiting sites). However, LR and KW were members of the EcLiPSE team; therefore, despite confidentiality assurances, their roles may have impacted on practitioners' willingness to discuss problems with trial recruitment, conduct or record trial discussions with parents. The majority of parents (75%) of children randomised and treated in the EcLiPSE trial consented to participate in some aspect of the Consent Study and qualitative recruitment stopped when data saturation was reached.<sup>14</sup> However, none of the 19/286 (4%) parents who declined their child's involvement in EcLiPSE consented to take part in the Consent Study; therefore, their views were not represented.

#### CONCLUSIONS

A pragmatic trial design, clear communication with parents, teamwork, research nurse support and leadership were key factors in successful recruitment and conduct of a challenging ED-led trial. Our study provides valuable insight from parents and practitioners to inform the design and conduct of future trials in this setting.

Twitter Mark D Lyttle @mdlyttle and Kerry Woolfall @kerry\_woolfall

Acknowledgements We would like to thank all parents and clinicians for taking the time to participate in interviews and focus groups. We would also like to acknowledge the participating EcLiPSE sites and investigators involved in recruitment to the Consent Sudy: Matthew Pereira, Susie Hardwick (Addenbrooke's Hospital, Cambridge University NHS Trust, Cambridge, UK); Shrouk Messahel, Joanne Noblet, Elizabeth D Lee, Rachel Greenwood-Bibby (Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, UK); Mark Buchanan, Sharon Hughes, Lucy Lewis (Arrowe Park Hospital, Wirral University Hospital NHS Trust, Liverpool, UK); Stuart Hartshorn, Louise Rogers, Juliet Hopkins (Birmingham Children's Hospital, UK); Mark D Lyttle, Daphin Fernandez, Sarah Potter, Holly R Lavigne-Smith, Phoebe Moulsdale, Alice Smith, Tracey Bingham (Bristol Royal Hospital for Children, UK); James Ross, Natasha Ramsey, Jo Hacking (Chelsea and Westminster NHS Foundation Trust, London, UK); Niall Mullen, Paul P Corrigan, Sarah Prudhoe (City Hospitals Sunderland NHS Foundation Trust, Sunderland, UK); Hani Faza, Gisela Robinson, Rachel C Sunley, Coral J Smith, Vanessa Unsworth (Derbyshire Children's Hospital, Derby, UK); John Criddle, Martin Laque, Alyce B Sheedy (Evelina London Children's Hospital, London, UK); Mark Anderson, Kirsty Devine, Kathryn Bell (Great North Children's Hospital, Newcastle upon Tyne, UK); Alex Scott, Ramesh Kumar, Sonia Armstrong (James Cook University Hospital, Middlesbrough, UK); Emer Sutherland, Fleur Cantle, Sinead Helyar, Paul Riozzi, Hannah Cotton (King's College Hospital, London, UK); Alice J Downes, Helen Mollard (Leeds General Infirmary, Leeds, UK); Damian Roland, Felix Hay (Leicester Hospitals, Leicester, UK); Chris Gough, Sonya Finucane (Nottingham University Hospitals NHS Trust, Nottingham, UK); Catherine Bevan, Rebecca Ramsay, Emily Walton (Royal Alexandra Children's Hospital, Brighton, UK); Julie-Ann Maney, Elizabeth Dalzell, Muriel Millar (Royal Belfast Hospital for Sick Children, Belfast, UK); Rachel J Howells, Andy Appelboam, Jennie Small, Daisy Mackle (Royal Devon and Exeter NHS Foundation Trust, Exeter, UK); Vince Choudhery, Stewart MacLeod, Ashleigh Neil (Royal Hospital for Children, Glasgow, UK); Jen Browning, Thom O'Neill, Julia Grahamslaw (Royal Hospital for Sick Children, Edinburgh, UK); Ami Parikh, Imogen Skene, Rhys Thomas (Royal London Hospital, London, UK); Katherine Potier de la Morandiere, Jill L Wilson, Donna Danziger (Royal Manchester Children's Hospital, Manchester, UK); Derek Burke, Shammi Ramlakhan, Jayne Evans, Julie Morcombe, Stuart Gormley (Sheffield Children's Hospital NHS Foundation Trust, Sheffield, UK); Jason M Barling, Katrina Cathie, Jane Bayreuther, Ruth Ensom (Southampton Children's Hospital, Southampton, UK); Yasser Iqbal, Sarah Rounding (St George's University Hospitals NHS Foundation Trust, London, UK); Joanne Mulligan, Claire Bell, Shona McLellan, Shona Leighton (University Hospital, Crosshouse, Kilmarnock, UK); Tina Sajjanhar, Maggie Nyirenda, Anastasia

Alcock, Laura Crome, Neil Williamson (University Hospital Lewisham, London, UK); Sara Edwards, Jeff Morgan, Colin V E Powell (University Hospital of Wales, Cardiff, UK); Chaniyil A Ramesh, Solomon Kamal-Uddin (Watford General Hospital, London, UK); Mike Linney, Katia Vamvakiti, Sharon Floyd, Gill Hobden (Western Sussex Hospitals NHS Foundation Trust, UK).

**Contributors** KW conceived and led the Consent Study. KW and LR developed study materials and topic guide. LR conducted the interviews. LR and KW analysed the data. KW wrote the initial manuscript draft, which was reviewed and developed with LR and MDL. All authors reviewed and approved the final manuscript. KW takes responsibility for the paper as a whole.

**Funding** National Institute for Health Research Health Technology Assessment programme (project no. 12/127/134).

**Disclaimer** The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. The researchers are independent from the funders. The funders had no role in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. All authors had full access to all of the data in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.

Competing interests None declared.

**Patient and public involvement** Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not required.

**Ethics approval** The Consent Study was approved as part of the EcLiPSE trial by the National Research Ethics Service Committee North West – Liverpool Central (15/NW/0090).

Provenance and peer review Not commissioned; externally peer reviewed.

**Data availability statement** No data are available. Consent was not sought for data sharing.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

#### ORCID iD

Kerry Woolfall http://orcid.org/0000-0002-5726-5304

### REFERENCES

- 1 Kaur G, Smyth RL, Williamson P. Developing a survey of barriers and facilitators to recruitment in randomized controlled trials. *Trials* 2012;13:218.
- 2 Treweek S, Mitchell E, Pitkethly M, et al. Strategies to improve recruitment to randomised controlled trials. The Cochrane Library 2010;1.
- 3 Flynn D, Knoedler MA, Hess EP, et al. Engaging patients in health care decisions in the emergency department through shared decision-making: a systematic review. Acad Emerg Med 2012;19:959–67.
- 4 Brierley J, Larcher V. Emergency research in children: options for ethical recruitment. J Med Ethics 2011;37:429–32.
- 5 Woolfall K, Frith L, Gamble C, et al. How parents and practitioners experience research without prior consent (deferred consent) for emergency research involving children with life threatening conditions: a mixed method study. BMJ Open 2015;5:e008522.
- 6 O'Hara CB, Canter RR, Mouncey PR, et al. A qualitative feasibility study to inform a randomised controlled trial of fluid bolus therapy in septic shock. Arch Dis Child 2018:103:28–32
- 7 Roper L, Sherratt FC, Young B, et al. Children's views on research without prior consent in emergency situations: a UK qualitative study. BMJ Open 2018;8:e022894.
- 8 Woolfall K, Frith L, Gamble C, et al. How experience makes a difference: practitioners' views on the use of deferred consent in paediatric and neonatal emergency care trials. BMC Med Ethics 2013;14:45.
- 9 Cook DJ, Blythe D, Rischbieth A, et al. Enrollment of intensive care unit patients into clinical studies: a trinational survey of researchers' experiences, beliefs, and practices. Crit Care Med 2008;36:2100–5.
- 10 Woolfall K, Young B, Frith L, et al. Doing challenging research studies in a patient-centred way: a qualitative study to inform a randomised controlled trial in the paediatric emergency care setting. BMJ Open 2014;4:e005045.
- 11 Woolfall K, Roper L, Humphreys A, et al. Enhancing practitioners' confidence in recruitment and consent in the EcLiPSE trial: a mixed-method evaluation of site training — a Paediatric Emergency Research in the United Kingdom and Ireland (PERUKI) study. *Trials* 2019;20:181.
- 12 Strauss A, Corbin J. Basics of qualitative research: techniques and procedures for developing grounded theory. 2nd edition. Thousand Oaks, CA: Sage, 1998.

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

- 13 Glaser BG. The constant comparative method of qualitative analysis. Soc Probl 1965:12:436–45
- 14 Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. *Int J Qual Health Care* 2007:19:349–57.
- 15 Reay H, Arulkumaran N, Brett SJ. Priorities for future intensive care research in the UK: results of a James Lind alliance priority setting partnership. J Intensive Care Soc 2014:15:288–96.
- 16 Donovan JL, Paramasivan S, de Salis I, et al. Clear obstacles and hidden challenges: understanding recruiter perspectives in six pragmatic randomised controlled trials. *Trials* 2014:15:5–6.
- 17 Inwald DP, Canter R, Woolfall K, et al. Restricted fluid bolus volume in early septic shock: results of the fluids in shock pilot trial. Arch Dis Child 2019;104:426–31.
- 18 Peters MJ, Woolfall K, Khan I, et al. Permissive versus restrictive temperature thresholds in critically ill children with fever and infection: a multicentre randomized clinical pilot trial. Crit Care 2019;23:69.
- 19 Wade J, Donovan JL, Athene Lane J, et al. It's not just what you say, it's also how you say it: opening the 'black box' of informed consent appointments in randomised controlled trials. Social Science & Medicine 2009;68:2018–28.

- 20 Realpe A, Adams A, Wall P, et al. A new simple six-step model to promote recruitment to RCTs was developed and successfully implemented. *Journal of Clinical Epidemiology* 2016;76:166–74.
- 21 Lemieux-Charles L, McGuire WL. What do we know about health care team effectiveness? A review of the literature. Medical Care Research and Review 2006:63:263–300.
- 22 Cook DJ, Blythe D, Rischbieth A, et al. Enrollment of intensive care unit patients into clinical studies: a trinational survey of researchers' experiences, beliefs and practices. Critical Care Medicine 2008;36:2100–5.
- 23 Lyttle MD, O'Sullivan R, Hartshorn S, et al. Pediatric Emergency Research in the UK and Ireland (PERUKI): developing a collaborative for multicentre research. Archives of Disease in Childhood 2014;99:602–3.
- 24 Strong S, Paramasivan S, Mills N, et al. 'The trial is owned by the team, not by an individual': a qualitative study exploring the role of teamwork in recruitment to randomised controlled trials in surgical oncology. *Trials* 2016;17:212.
- 25 O'Brien BC, Harris IB, Beckman TJ, et al. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med 2014;89:1245–51.

### Consent study parent questionnaire example questions

1. Please indicate how strongly you agree or disagree with the following statements by placing a circle around the answer that best fits your opinion or decision:

and a district that sest ins your opinion of acc	Agree	Neither Agree nor Disagree	Disagree
a. The doctor or nurse checked that it was a convenient time to discuss research before discussing EcLiPSE	1	2	3
b. The information I received about EcLiPSE was clear and straightforward to understand	1	2	3
c. I understood why consent for the use of my child's information in EcLiPSE was sought	1	2	3
d. I had enough opportunity to ask questions about EcLiPSE	1	2	3
e. I would be happy for my child's information to be used in EcLiPSE <b>without</b> being asked (e.g. consent would not be sought)	1	2	3
f. I was satisfied with the consent process for EcLiPSE	1	2	3
g. It was difficult to take in the information I was given about EcLiPSE	1	2	3
h. It was difficult to make a decision about EcLiPSE	1	2	3
i. I made this decision	1	2	3
j. Someone took this decision away from me	1	2	3
k. I was not in control of this decision	1	2	3
I. The decision about the research was inappropriately influenced by others	1	2	3
If the answer to this question is "Agree" please state who you think influenced the decision about the research:			

### 2. Did you consent for your child's information to be used in EcLiPSE?

Yes [ ] (Go to question 3)

No [] (Go to question 4)

# 3. What were your reasons for providing consent for your child's information to be used in EcLiPSE? Please tick all that apply <u>AND THEN CIRCLE YOUR MAIN REASON</u> (e.g. $\checkmark$ )

a. To help my child	
b. To help other children in the future	
c. I felt that medical studies like EcLiPSE are important	
d. Because I trusted the doctor or nurse who explained EcLiPSE	
e. My child's seizure stopped	
f. I didn't feel comfortable saying no to the nurse or doctor who explained the study	
g. Other (Please state):	

4. <u>If you did not provide consent</u>, please provide your reasons for deciding that your child's information would not be used in the EcLiPSE study (If you do not wish to do so please leave this space blank):

5. We would value any comments or suggestions you have to improve the recruitment and consent process for EcLiPSE, please use the space below:

Consent study topic guide parent interview example

Section 1	Section 1: Demographic information.		
Do you m	ind if I start by asking a few questions about you and your child?		
1.1	Where do you live?		
	What is your postcode?		
	Would you describe yourself as being: employed or unemployed?		
	- (If employed, what is your profession? If Unemployed, what was your previous occupation?)		
1.2	How old is your child who was entered into EcLiPSE?		
1.3	Is your child a girl or a boy?		
1.4	What would you describe as being your first language?		
1.5	In which hospital did your child receive treatment in the EcLiPSE trial?		
1.6	How long ago was this? request month and date?		
1.7	Has your child had seizures before this episode?		
	If yes, does your child suffer from a condition which causes seizures? (Explore how long they have had them for, usual treatment, usual frequency, knowledge of the hospital, staff, process of treating seizures)		
Section 2	: The EcLiPSE consent process		
2.1	Would you mind if I start by getting an overall picture of what happened when you first heard about the ECLIPSE trial could you tell me a bit about that? (Explore any knowledge about the trial before admission)		
2.2	During the actual treatment in the room where your child was having the seizure, did you ask any questions about the study? What were you told?		
2.3	Did you see any leaflets or posters about the trial?		
	If Yes, where were the posters (Prompt: on the wall in the ED?)		
	If Yes, was this before or after the nurse approached you about the trial (Explore initial reactions if before)		
	Could you tell me what you thought about the leaflets/posters?		
2.4	Did one of the nursing staff looking after your child introduce you to the research nurse or doctor?		
2.5	Did the research nurse/doctor check with you that it was a good time to talk about research?		
2.6	Could you tell me what they explained about ECLIPSE?		
2.7	Was there anything that you found: a) unclear b) surprising?		
2.8	Is there anything else that sticks out in your mind about the discussion?		
2.9	How was the nurse/doctor in dealing with you that day?		
2.10	Could you tell me about any written information you were given by a nurse or doctor about the trial?		
2.11	When did you receive this information (Prompt: explore written and verbal and time point)		
2.12	Did you read the information leaflet?		
2.13	What did you think about the information leaflet?		
2.14	Was there anything that you found: a) unclear? b) surprising?		
2.15	Could the information leaflet be improved in any way? (Prompt: If so, how?)		
2.16	This is a question I ask all parents and it's not a test, but just so we can gage whether the trial is being explained clearly enough I wanted to know whether you		
	Could you tell me what the ECLIPSE trial was looking at?		

2.17	What do you think about the use of deferred consent in an emergency situation (for example, when a child has entered hospital via A&E or born very early)?
2.18	Explain: Families involved in ECLIPSE provided consent after their child was given the treatment. We call this deferred consent or also known as research without prior consent
	Did you know that your child had been given either Keppra or Phenytoin as part of the EcLiPSE trial before the nurse approached you for consent?
	If NO
	A) could you tell me how you feel about that now that you know?
	If YES a) How did the nurse/doctor explain deferred consent to you?
	b) What did you think when you found out that your child had already been entered into the trial before you were approached by the doctor or nurse about your consent?
	c) Were you surprised at all? If YES, Could you tell me a bit about that?
2.19	Do you think nurses should briefly discuss the trial with parents in the emergency situation and provide them with the opportunity to saying yes or no to their child's involvement in the trial before the drug has been given?
	a) Do you think parents would be able to understand such information in this situation?
	b) Do you think parents might feel under pressure to make a decision in this situation?
2.20	Have you ever heard of the drugs Keppra or Phenytoin before your child's involvement in the EcLiPSE trial?
	If yes, EXPLORE a) how are you familiar with the drug?
	b) Do you think that your knowledge of the drug/s influenced your views about the trial? If yes, Explore- how did it influence your views?
	c) Would you have felt differently about the use of deferred consent if EcLiPSE involved a drug that you were not familiar with?
2.21	Did the nurse/doctor explain to you that blood samples were taken for the trial?
	If yesdo you know whether blood samples were taken before or after the doctor asked for your deferred consent?
	If Before: how did you feel about deferred consent for blood samples?
2.23	Children taking part in ECLIPSE were split into two groups by a process called randomisation. Could you tell me if this process was explained to you?
	How was this process explained?
0.04	Was there anything about this process that you were unclear about?
2.24	Did you ask any questions about randomisation? (If yes, did this help you make a decision about your child taking part in the trial?)
2.25	Did you ask the nurse/doctor which drug your child had been given?  If YES,
	a) when did you ask this question? (Explore was it before the researcher came to speak to you or during that discussion?)
	b) how did you feel when they told you which drug your child had been given?
	c) how would you feel if your child received this drug again in the future?
	Standard response to question of 'can we have Keppra again'?
	Emphasise:
	If the child attends again and needs any second-line treatment and the ED team know the child was randomised then he/she cannot be put into the trial again and should receive the standard drug – phenytoin. If the family want their child to receive Keppra it will be up to the particular ED team medic at that time to decide what to do.
2.26	How long did you get to think about whether you wanted your child's information to be used in ECLIPSE? Do you think this was long enough?

	Did you have the opportunity to ask questions about the study?
	Did you ask any? (Prompt, what questions did you ask?, if not, why not)
	How long do you think people should be given to think about taking part in a trial?
2.27	I'd like to ask you now about the questionnaire you were asked to complete at the hospital. Did you complete the questionnaire?
2.28	Do you think it was the right time to complete the questionnaire? (Prompt when would have been a better time?)
2.29	Is there any way you think the questionnaire could have been improved? (Prompt the questions asked, the length of the questionnaire, provided via web link?)
2.30	Is there anything about how ECLIPSE was explained to you that could have been handled a bit differently?
2.31	Did you provide consent for your child to take part in the ECLIPSE trial?
2.32	In making the decision about your child's participation in ECLIPSE, what sort of things went through your mind?
2.33	Some parents have said that it's difficult to take in all the information about a trial when their child is ill. Could you tell me about what it is like to have all this information given to you and for you to think about it at this difficult time
2.34	Could you tell me if you found anything about the trial unclear or confusing?
2.35	Was there anything you found particularly helpful in making up your mind?
2.36	Was there anything you found unhelpful?
2.37	How hard was this decision?
2.38	Was there anything specific that influenced your decision? (Prompt: did you discuss it with anyone who helped or made the decision more difficult?)
2.39	Would you mind telling me what were your reasons for (providing consent/not providing consent)?
Section 3 I	Decision making
3.4	Did you feel that your child may benefit from taking part in the trial?
3.5	Could you describe the possible benefits you expected your child to gain from taking part in ECLIPSE?
3.6	Did this influence your decision in any way?
3.7	Did you have any concerns about your child taking part?
3.8	What were the possible risks to your child in participating?
3.9	In making your decision, did you think about how the research may benefit other children in the future?
3.10	Apart from the doctor or nurse, did you discuss it with anyone else? [Can you tell me a bit about that?]
3.11	Did you ever feel under pressure in making your mind up? [If yes: where did that pressure come from]?
3.12	Did you know the doctor or nurse a) at the ED b) at the recruitment conversation?
3.13	In your opinion, did your relationship with the doctor or nurse who asked you to take part in ECLIPSE influence your decision? [If so, could you tell me a bit more about that?]
3.14	In making your decision how important was their manor, such as what they said and how they said it?
3.15	Now that a little time has passed, how do you feel about the decision you made?
3.16	Have you thought of any questions you would have liked to have asked that you didn't ask at the time?
Section 5 Im	proving the trial and research discussion in the future
5.1	When do you think is the best time to approach parents to obtain consent in an emergency situation? (Prompt, ECLIPSE is within 24 hours of admission)

5.2	When do you think parents should be consulted about their child's involvement in an emergency trial [Prompt: what if the trial involved a new drug? Could you tell me a bit more about your reasons for this?]		
	Is deferred consent acceptable for that type of research?		
5.3	Who do you think should approach the parents about a trial?		
	Prompt: Do you think it should be a doctor or nurse involved in a child's care who approaches parents about a trial? Do you think it should be someone separate from the care team? Could you tell me why you think this?		
5.4	Before the ECLIPSE trial, have you ever been approached to consent for your child to participate in medical research? (If yes) [If more than one go through the trial prior to ECLIPSE]		
	Could you tell me a bit more about it?		
	Did you provide consent for your child to take part in the research?		
	Could you tell me a bit about what informed your decision (not) to take part?		
	Was anyone else involved in making this decision?		
	Could you tell me anything about being approached about this research that has stuck in your mind?		
5.5	Do you think that research to improve treatments for critically ill children should be done?		
5.6	What advice would you give to researchers who approach families about a clinical trial in an emergency situation?		
5.7	Finally, do you feel that taking part in medical research is important? If so, could you tell me why?		
Section 6	Section 6 Anything else?		
6.1*	Is there anything else that you think is important to mention that I have not covered?		